NMD Pharma

Our #NMDResearchScientists, Marianne Skals, Martin Broch-Lips, Martin Brandhøj Skov, Anders Riisager, Judith Leermakers-Ceelen, and Thomas Holm Pedersen, experts in muscle physiology, together with collaborators from Health - Aarhus University, Mayo Clinic College of Medicine and Science and Martini General Hospital Groningen recently published a peer-reviewed manuscript in the prestigious Nature Communications Journal.  This manuscript describes the results of preclinical experiments using a therapeutic agent targeting the chloride ion channel 1 (ClC-1) in animals that had been given a neuromuscular blocking agent (#NMBAs). NMBAs are commonly used during surgery to induce skeletal muscle relaxation by blocking postsynaptic acetylcholine receptors at the neuromuscular junction of skeletal muscle fibers. Researchers demonstrated that inhibition of the skeletal muscle-specific ClC-1 ion channel markedly accelerated recovery of both single contraction (twitch) and sustained contractions (tetanic) in a rat model mimicking neuromuscular blocking-agent induced muscle block used during surgery. These results are significant as it could be the first safe #reversalagent that can reverse any nondepolarizing blocking agent and, furthermore, show superiority to existing reversal agents in recovering intense muscle contractions. It also marks the first intravenous use of our ClC-1 inhibitors, and the use in a condition other than a rare neuromuscular disease, showing that this technology can be used in a broad range of applications. Read the full paper here: https://lnkd.in/dbgY62FK #NMDPharma #Biotech #Pharma #Innovation #skeletalmuscle #targeteddrugtherapy #precisionmedicine #clc-1ionchannel #anesthesia #muscleactivation

NMD Pharma is proud to recognize International Stress Awareness Day, which raises awareness about the importance of stress management and the impact stress can have on mental and physical health. On average, we each spend one third of our lives at work, meaning that safe and healthy working environments have enormous potential to positively influence our stress levels and #MentalHealth. At NMD Pharma, we encourage team members to support each other to maintain a strong and balanced working environment and to speak up when they are stressed. Channelling our Passion for Movement to build healthy habits, today we have hosted a series of #StressAwareness initiatives, including a morning session, a relaxing online yoga class led by Vera K., Director of Clinical Development and a reflective team walk and talk. Together, we make stress a topic we can openly discuss and manage. #StressAwarenessDay #Biotech #NeuromuscularDisease #TeamBuilding

Later this month, our CEO, Thomas Holm Pedersen, and SVP, Corporate and Commercial Strategy, Dan Brennan, will be in London for this year’s Jefferies Global Healthcare Conference. Held from 19-21 November, this year’s gathering marks the 15th anniversary of Europe’s largest healthcare-dedicated conference, and we look forward to joining other leading #biotech and pharma executives, #investors and potential partners to discuss NMD Pharma’s corporate strategy and recent progress developing novel treatments to improve muscle function and quality of life of patients with neuromuscular diseases. If you will also be on the ground in London and would like to hear more about our novel skeletal muscle-specific chloride 1 ion channel (ClC-1) inhibitor approach, which has the potential to improve muscle power and endurance in patients living with severe neuromuscular disorders, please contact contact@nmdpharma.com to set up a meeting. #JefferiesHealthcare #InvestorConference #Innovation #NeuromuscularDisease #NMDPharma

NMD Pharma will be at the upcoming Synapse DK - Life Science Connect Career Fair in Aarhus on October 29, 2024. As a leading biotech company, we're always on the lookout for talented individuals to join our growing team as our lead program, NMD670, progresses through multiple clinical trials. If you’ve ever wondered what it’s like working for a #biotech company, Martin Brandhøj Skov, Innovation Manager, and Jesper Emil Jakobsgaard, Research Scientist, will be there to answer your questions and share insights into the dynamic world of #research in neuromuscular diseases. Martin will be giving a talk about NMD Pharma from 16:30-17:00. Sign up for the career fair here: https://lnkd.in/dW9NhUTB Check out what a day in the life of a research scientist at NMD Pharma looks like here: https://lnkd.in/d9AkuPQA #LifeScienceCareerFair #Innovation #ClinicalResearch #NeuromuscularDisease

Our CEO, Thomas Holm Pedersen and COO, Thomas Kongstad Petersen will be at the #BIOEurope conference in Stockholm, Sweden from 4-6 November. We look forward to connecting with other #biotech leaders and #investors and sharing the latest updates on NMD670, our novel chloride 1 ion channel (ClC-1) modulator skeletal muscle-targeted therapy with the potential to improve muscle power and endurance in patients living with severe neuromuscular diseases. If you are interested in learning more, please contact us by email contact@nmdpharma.com.   #InvestorConference #NMDPharma #Innovation #NeuromuscularDisease #Collaborations

Please join us in welcoming Trine Schütt to the NMD Pharma team as Senior #Toxicologist and Animal Welfare Officer. Trine is a veterinarian by training with a PhD in veterinary neurology. She comes with extensive experience within drug development from LEO Pharma where she was the Principal Professional/Developmental Toxicologist and Animal Welfare Officer.  In her new role at NMD Pharma she will work closely with the non-clinical development team to advance our pipeline molecules and furthermore ensure that all our operations and external collaboration partners are compliant with respect to high standards of animal welfare. Welcome Trine! #NewHire #WelcomeToTheTeam #NMDPharma #Biotech #Innovation

We’re pleased to announce that Alok Singh joined us last month as a Senior Data Manager at our office in Copenhagen. Alok has many years of experience in data management EDC set-up, conduct, and closeout, including at Ascendis Pharma, LEO Pharma and Novo Nordisk. With two Phase 2 trials of our lead development program, NMD670, already underway in spinal muscular atrophy (#SMA) and generalized myasthenia gravis (#MG), and a third in Charcot-Marie-Tooth disease anticipated to start shortly, Alok’s expertise will be invaluable as we continue to progress into a Phase 3-ready organization. Welcome to the team, Alok! #NMDPharma #Innovation #Research #NeuromuscularDisease

Next week, Vera K., Director of Clinical Development and Martin Brandhøj Skov, Innovation Manager at NMD Pharma will be giving three oral presentations and Dan Brennan, SVP Corporate and Commercial Strategy will be presenting a poster at the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting. Taking place from 15-18 October, this year’s programme offers a diverse selection of valuable in-person sessions with the world’s foremost academic and scientific experts in the field of #NeuromuscularDisease, alongside the latest cutting-edge #research. NMD Pharma’s oral and poster presentations will take place during the Myasthenia Gravis Foundation of America, Inc. (MGFA) Scientific Session, showcasing our preclinical and clinical work establishing the novel therapeutic potential of ClC-1 ion channel inhibition for several neuromuscular diseases, including myasthenia gravis (#MG). By inhibiting the CIC-1 channels, NMD670 amplifies muscle responsiveness, enabling consistent contractions even when the signal transmitted to the muscle is weak due to disease processes. The session will be held on Tuesday, 15 October from 8:00-12:00ET in Chatham Ballroom A – please stop by to learn more about our novel approach, or reach out to Dan to set up a meeting. For more information, read the full press release: https://lnkd.in/gd7CfQSR #Biotech #AANEMAnnualMeeting #AANEMinSavannah #NMDPharma #Innovation #MyastheniaGravis #MGFA #RareDisease

We are looking for a Senior Drug Substance Specialist! As NMD Pharma continues its growth trajectory following its successful recent fundraising, we are seeking a motivated and highly skilled late-stage drug substance specialist to contribute towards our mission of bringing life-changing therapies to patients living with neuromuscular diseases. Find out more here: https://lnkd.in/gPVcrJ9A

Looking for a new challenge as our next Team Leader, Administration? We seek a dynamic team member to help shape and optimize our administrative processes. Know someone who’s the perfect fit? Share this opportunity with them! Find out more and apply here: https://lnkd.in/gs5Z_3a5 We can’t wait to read your application!